On May 30 (Monday) another meeting of the Transparency Council.
AOTMiT: Transparency Council, incl. o pancreatic cancer drug
Published May 24, 2022 10:56
Źródło: AOTMiT
The agenda is:
Preparation of a position on the legitimacy of changing medical technology regarding guaranteed services in the field of procedures ICD-9: 84.502 - introduction of growth factors of autogenous origin and ICD-9: 84.503 - introduction of growth factors from stem cells with an indication of the scope of indications for use.
Preparation of a position on the evaluation of Lynparza (olaparibum) under the drug program: "Treatment of patients with metastatic pancreatic adenocarcinoma or ineligible for radical treatment with the presence of mutations in BRCA 1/2 genes (ICD-10 C 25.0, C 25.1, C 25.2, C 25.3, C 25.5, C 25.6, C 25.7, C 25.8, C 25.9) ”.
Preparation of a position on the validity of granting approval for the reimbursement of Betaquik foodstuffs for particular nutritional uses in the indications: deficit of the GLUT-1 glucose transporter; drug-resistant epilepsy.
Preparation of opinions on draft health policy programs of local government units:
"Program for the prevention and early detection of overweight and obesity among children in grades IV-VIII, primary school students from the Radom County, for the years 2022-2023",
"Health program for secondary prevention of cervical cancer self-sampling - screening based on the HPV test" (Kobierzyce commune).
Source: AOTMiT
